1,720 Shares in Cencora, Inc. (NYSE:COR) Purchased by Zacks Investment Management

Zacks Investment Management acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,720 shares of the company's stock, valued at approximately $386,000.

A number of other large investors have also added to or reduced their stakes in COR. Hickory Asset Management Inc. purchased a new stake in Cencora in the 4th quarter worth $572,000. Sylvest Advisors LLC purchased a new position in Cencora during the 4th quarter worth $1,105,000. Insight Wealth Strategies LLC raised its holdings in shares of Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after acquiring an additional 11,232 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after acquiring an additional 1,995 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. grew its holdings in Cencora by 71.1% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock worth $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analyst Ratings Changes

COR has been the subject of a number of recent analyst reports. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Bank of America raised their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $284.55.

Insider Activity at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at $3,934,326.20. This represents a 21.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,223 shares of company stock valued at $13,580,967 in the last 90 days. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Down 0.5 %

COR stock traded down $1.56 during trading hours on Wednesday, hitting $284.71. The company's stock had a trading volume of 1,992,164 shares, compared to its average volume of 1,512,387. The company has a market capitalization of $55.21 billion, a PE ratio of 40.50, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The stock has a 50 day moving average price of $265.58 and a two-hundred day moving average price of $248.02. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.